Pentosan Polysulfate

FDA Approved

Pentosan Polysulfate

A semi-synthetic polysaccharide researched for joint health, cartilage repair, and as a potential treatment for Maculopathy. Not technically a peptide but widely studied alongside peptide protocols.

SubQ injectionOralJoint HealthHealing & Recovery

Dose

3 mg/kg

Route

SubQ injection, Oral

Cycle

6-12 weeks, as per research protocol

Storage

Store at 2-8°C (36-46°F), protected from light

What is Pentosan Polysulfate?

Pentosan Polysulfate (PPS) is a semi-synthetic sulfated xylan polysaccharide that is widely researched for its potential in joint health, particularly in scenarios involving cartilage degradation and inflammation. While not a peptide, its mechanisms of action, such as stimulating synovial fluid production and inhibiting cartilage-degrading enzymes, make it a subject of interest alongside peptide research protocols. Early research also investigates its potential for retinal protection, specifically in Maculopathy. It exhibits anti-inflammatory effects through mechanisms similar to heparin.

Key Benefits

  • Cartilage protection
  • Joint lubrication improvement
  • Anti-inflammatory in joints
  • Potential retinal protection research

Mechanism of Action

  • Stimulates synovial fluid production
  • Inhibits enzymes that break down cartilage
  • Anti-inflammatory via heparin-like activity

Best For

  • Joint health research
  • Arthritis research
  • Cartilage repair

Body Systems

MusculoskeletalOcular

🐾 Griffin Says...

Not a traditional peptide but commonly researched alongside peptide joint health protocols. Popular in veterinary applications for horses and dogs with arthritis. Human research is growing, particularly for osteoarthritis and joint space preservation.

Molecular Information

Molecular weight

4000-6000 Da (variable, average ~4500 Da)

Length

N/A

Type

Semi-synthetic polysaccharide

Amino acid sequence

N/A

Pentosan Polysulfate is a complex sulfated polysaccharide, not a peptide. Its structure is derived from xylan, a plant hemicellulose.

Pharmacokinetics

Time to peak

1-2 hours (subcutaneous)

Half-life

4 h

Time to clear

Approximately 24 hours

DoseEstimated plasma concentration24 h

Widely discussed in pharmacokinetic studies for pentosan polysulfate sodium.

Research Indications

  • Osteoarthritis

    Researched for its ability to protect cartilage, improve synovial fluid viscosity, and reduce inflammation in animal models and early human trials of osteoarthritis.

  • Cartilage Degradation Prevention

    Studies indicate PPS can inhibit enzymes (e.g., matrix metalloproteinases) responsible for breaking down cartilage components like proteoglycans and collagen.

  • Subchondral Bone Health

    Explored for its potential role in influencing subchondral bone remodeling, which is critical for overall joint integrity.

Research Protocols

GoalDoseFrequencyRoute
Cartilage protection and joint lubrication in osteoarthritis models (subcutaneous)3 mg/kgOnce weeklySubcutaneous
Cartilage protection and joint lubrication in osteoarthritis models (oral)5-10 mg/kgDaily or every other dayOral
Investigation of retinal protective effectsVaried, typically 1-3 mg/kgWeekly or bi-weeklySubcutaneous
Acute inflammatory response modulation2 mg/kgEvery 3-4 days for short durationSubcutaneous

Research protocols commonly discuss maintaining a consistent dosing schedule for optimal observation of effects.

Peptide Interactions

  • Warfarin

    Both compounds have anticoagulant properties; co-administration may increase the risk of bleeding. Close monitoring of coagulation parameters is commonly discussed.

    Use Caution
  • Aspirin/NSAIDs

    These compounds can also affect platelet function or coagulation. Combining with PPS may increase bleeding risk, requiring careful observation in research subjects.

    Monitor Combination
  • Heparin

    Due to similar anticoagulant mechanisms, co-administration with heparin is generally not advised in research protocols unless under highly controlled conditions due to a significantly increased risk of hemorrhage.

    Avoid
  • Glucosamine/Chondroitin

    These are often investigated together in joint health research; no direct adverse interactions are commonly reported, and potential synergistic effects are sometimes explored.

    Compatible
  • Corticosteroids

    While both can reduce inflammation, corticosteroids have distinct mechanisms and side effects. Monitoring for overall safety and efficacy is prudent if co-administered in research.

    Monitor Combination

How to Reconstitute

  1. 1Gather necessary supplies: vial of lyophilized Pentosan Polysulfate, bacteriostatic water for injection, sterile syringes, and alcohol wipes.
  2. 2Clean the rubber stopper of the peptide vial and the bacteriostatic water vial with alcohol wipes.
  3. 3Using a sterile syringe, draw the appropriate amount of bacteriostatic water (commonly 1 mL per vial unless specified otherwise by manufacturer guidelines) and slowly inject it into the lyophilized Pentosan Polysulfate vial, aiming for the side of the vial to prevent foaming.
  4. 4Do not shake the vial vigorously. Gently swirl the vial to allow the powder to fully dissolve. This may take a few minutes.
  5. 5Visually inspect the reconstituted solution for any particulate matter or discoloration. The solution should be clear and colorless.
  6. 6Once dissolved, the reconstituted solution is ready for administration or storage according to research protocols.

The reconstitution of Pentosan Polysulfate should be performed under sterile conditions to maintain product integrity and safety for research administration.

What to Expect

  • Weeks 1-2: Initial systemic absorption and distribution, with potential for mild anti-inflammatory effects beginning.
  • Weeks 3-5: Research subjects may begin to exhibit early signs of improved joint comfort or reduction in inflammatory markers, particularly with consistent administration.
  • Weeks 6-8: More pronounced effects on joint mobility, cartilage health, or specific research endpoints (e.g., retinal health) may become observable.
  • Weeks 9-12: Continued improvements and stabilization of observed benefits, with peak efficacy often noted around this period in research settings.
  • Post-cycle: Maintenance of benefits may vary; some research protocols discuss continued or intermittent dosing strategies.

Side Effects & Safety

EffectFrequencySeverity
Bleeding riskUncommonModerate
NauseaUncommonMild

Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾

Open Calculator

Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.